AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00248612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive muscle relaxation therapy (PMR)
Description: For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
Study NCT00248612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo medication
Description: For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
Study NCT00248612 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication
Description: For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
Study NCT03079375 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: basic intervention
Description: medication review
Study NCT03079375 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: extended intervention
Description: medication review, medication interview before discharge and follow-up
Study NCT00991276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: capsules; 300 mg once-per-day; 4 weeks of treatment
Study NCT00991276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules; 0 mg once-per-day; 4 weeks of treatment
Study NCT00991276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole
Description: capsules; 0.5 mg once-per-day; 4 weeks of treatment
Study NCT01214902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constraint induced movement therapy (CIMT)
Description: soft mitten worn on the non hemiplegic hand
Study NCT01214902 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: play
Description: play which encourages the use of the hemiplegic hand
Study NCT04660084 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultra-rapid molecular point-of-care testing
Description: Ultra-rapid molecular testing (UR-MT) comprises automated detection using the new BioFire® FilmArray® Pneumonia plus platform (Biomérieux). The total turn-around time is \<2 hrs.~The UR-MT is combined with standard of care, comprising:~Microbiological processing per current standard of care entails culture of respiratory tract samples according to national protocols to detect respiratory bacteria, identified using biochemical methods and/or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF MS). Respiratory viruses are identified using real-time PCR (for metapneumovirus, rhinovirus, influenza A, influenza B, parainfluenza 1-3, RSV and SARS-CoV-2). The total turn-around time is up to 48 hrs.
Study NCT03035240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Education
Description: Participants randomized to financial education will undergo a year long financial education. This involves 9 weeks of weekly classes followed by one on one coaching for a year.
Study NCT01896492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NAC
Description: NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
Study NCT01896492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC
Description: NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
Study NCT00579631 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire or Interview
Description: Complete a self-report survey once over the telephone or by mail. The questions are about your health beliefs and behaviors, your current health, and your mood. It should not take longer than 45 minutes to complete. About 15 of these people will participate in an additional, short audiotaped interview about sun protection.
Study NCT03241186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1mg/kg
Study NCT03241186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3mg/kg
Study NCT03241186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480mg
Study NCT03201341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrooculogram (EOG)
Description: The acquisition of the surface EOG activity will be carried out by means of 3 surface electrodes, one of which, referred to as a reference, is placed on a bone zone (the glabella, above the nasion) and two others placed on The temples, coupled to an EOG amplifier.
Study NCT03201341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surface Electromyography (EMG)
Description: In behavioral or transcranial stimulation protocols, surface EMG activity may be recorded for further analysis. No protocol included in this project will involve the recording of intramuscular electromyographic activity, which is invasive and involves the implantation of needle electrodes into the muscles.
Study NCT03201341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrodermal response
Description: The electrodermal response is a useful, simple and reproducible method for recording sweat gland activity that reflects autonomic nervous activity. Recordings will be made using traditional devices, including an amplifier (Delsys or BrainAMP or equivalent) as well as disposable electrodes.
Study NCT03201341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Changes in skin temperature
Description: The skin temperature will therefore be recorded during behavioral protocols using techniques for manipulating the representation of the body (perceptual illusion, prismatic deviation, etc.) using a specific measuring device.
Study NCT03201341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Whatever the protocol, a diffusion tensor MRI (DTI) acquisition sequence as well as an image of the entire brain and high spatial resolution (T1 weight, 1x1x1 mm, nasion markers and pre-atrial points) will be acquired (Total duration: 20 minutes).
Study NCT03201341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MEG
Description: During the examination, the subject will have to perform tasks comparable to those described for the fMRI procedure, but with the additional possibility, offered by the MEG environment, of performing pointing or seizing of objects, provided that the Trunk and the subject's head be held in place by a suitable restraint system.
Study NCT03201341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transcranial magnetic stimulation (TMS)
Description: TMS is a non-invasive technique that uses very short (\~ 100μs) magnetic pulses applied to the scalp to transiently and focally disrupt or improve the functioning of neuronal populations in the underlying superficial cortical regions.
Study NCT03201341 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transcranial electrical stimulation in direct current (tDCS)
Description: The tDCS consists in passing a current of low intensity (generally ≤ 1mA to stimulate the cerebral cortex) between an anode and a cathode placed on the scalp, a part of this current crossing the tissues, and in particular the cortical regions situated between these two Electrodes. Generally, if the cathode is placed on the region of interest, it will be inhibited, while it will be energized if the anode is positioned thereon.
Study NCT03485001 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: This group will not receive argon laser medical treatment; instead, they will be only exposed to the slit lamp light.
Study NCT03485001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Argon Laser Treatment
Description: This group will receive argon laser medical treatment to the body and head of pterygium
Study NCT04084990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S9 VPAP Adapt
Description: Auto-titrated positive airway pressure
Study NCT02612129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arimoclomol
Study NCT02129062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given orally 560 mg daily (dispensed as 4 x 140-mg capsules)
Study NCT02129062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01954901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Study NCT01954901 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric room air
Study NCT03450629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate Ophthalmic Suspension
Description: PDP-716
Study NCT03450629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Tartrate Ophthalmic Solution
Description: Three Times Brimonidine Tartrate Ophthalmic Solution
Study NCT01109849 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavior therapy
Description: combination of individual and group parent training plus school consultation
Study NCT01109849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release (ER) methylphenidate product
Description: medication to be taken daily for duration of study unless assigned to weight promotion arm
Study NCT01109849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: monitoring
Description: monthly weight, height and BMI checks
Study NCT01109849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drug holiday
Description: switch from seven day a week dosing to medication only on school days
Study NCT01109849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caloric supplement
Description: continue current ADHD regimen and add one 8oz liquid caloric supplement at night
Study NCT01720043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Single dose of Velcade (1.0-1.3 mg/m2 dose)
Study NCT02527850 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: B-cure laser
Study NCT02527850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B-cure laser
Study NCT03504449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiotherapy
Study NCT02157714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX002
Study NCT02157714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02392338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid procedure
Description: Eletrophysiologic study via femoral vein approach to confirm pulmonary vein isolation lesion and box lesions in left atrium
Study NCT02612129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03252938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP321
Description: LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
Study NCT03252938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab i.v.
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per the schedule specified in the respective arm.
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered as per the schedule specified in the respective arm.
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab will be administered as per the schedule specified in the respective arm.
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
Study NCT03726879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab Emtansine
Description: Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
Study NCT00913835 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Olaratumab
Description: 20 milligrams per kilogram (mg/kg) administered by intervenous (IV) infusion every 2 weeks (14 days). Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity
Study NCT00913835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: 20 milligrams per kilogram (mg/kg) administered by intervenous (IV) infusion every 2 weeks (14 days). Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity
Study NCT00913835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal doxorubicin
Description: 40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity
Study NCT00913835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: 40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity
Study NCT01827306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biofreeze
Study NCT01629888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).
Description: 1 = Intervention 1 (3 test products/day)
Study NCT01629888 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters
Description: 2 = Intervention 2 (3 control products/day)
Study NCT02431026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling pack activated Excel Cryo Cooling Collar
Description: Cooling pack will be activated before insertion into collar. The first cooling pack will be replaced 20 minutes later with a new, activated cooling pack.
Study NCT01505985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional Supplement
Description: Specialized nutritional supplement for seniors
Study NCT01505985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo product with no specific nutrients
Study NCT03928015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunctive dronabinol
Description: 5mg BID and adjusting within the range of 2.5mg - 10mg BID, minimum of 48 hours, as an adjunct to systemic analgesics
Study NCT03928015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic analgesics
Description: multimodal analgesia including opioid and non-opioid analgesics
Study NCT03202173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 10% fluorescein
Description: The nasopharyngeal lesions were first identified endoscopically by nasal endoscope. Then, an initial dose of 0.5 mL prior to the examination with a maximum dose of 2.5 mL of 10% fluorescein (IV; Akorn Inc, Lake Forest, Illinois, USA) during the measurement procedure was defined according to the experiences of workgroup in the gastrointestinal tract.
Study NCT03202173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 10% fluorescein
Description: The nasopharyngeal lesions were first identified endoscopically by nasal endoscope. Then, an initial dose of 0.5 mL prior to the examination with a maximum dose of 2.5 mL of 10% fluorescein (IV; Akorn Inc, Lake Forest, Illinois, USA) during the measurement procedure was defined according to the experiences of workgroup in the gastrointestinal tract.
Study NCT01737723 — intervention group
Intervention type: DEVICE
Intervention: Neurokeeper stroke detector
Description: Monitoring stroke patients
Study NCT03094377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory therapy
Description: Sensory stimulation, motor training and ADL training
Study NCT03094377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training
Description: Motor training and ADL training
Study NCT03753269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil Hydrochloride
Description: 2.5mg fasudil hydrochloride (diulted to 15ml by 0.9% saline )will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
Study NCT03753269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline
Description: 15ml 0.9% saline will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
Study NCT02706678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus sustained-release capsule
Description: Oral
Study NCT04679363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active release technique
Description: ART will be performed on upper trapezius and sternocleidomastoid, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. ART will be performed in supine position with a pillow under knees. After the shortened area of the targeted muscle is identified, soft tissue mobilization with active movement and passive overpressure will be applied. The active movement in technique will be from shortened position of muscle to lengthened position.
Study NCT04679363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric relaxation
Description: PIR will be performed on upper trapezius and sternocleidomastoid muscles, starting from 5 repetitions in 1st and 2nd week and progressing to 10 repetitions in 3rd week. The patient will be instructed to move the ear towards the shoulder of the affected side, against the resistance of the therapist's hands with minimum force (only 20% of their total force). The patient will be instructed to perform isometric contraction of the affected side along with inhalation and position for 10 seconds. Then the patient will exhale completely and relax. During this relaxation phase head and neck are taken further away from ipsilateral shoulder and ipsilateral shoulder is pushed downward until next restriction is met.
Study NCT04408183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-1200
Description: GLS-1200 is given as a nasal spray using an atomizer
Study NCT04408183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given as a nasal spray using an atomizer
Study NCT01555983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaporization of Cannabis
Description: Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
Study NCT01555983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaporization of Cannabis
Description: Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
Study NCT00914173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scanlaf Circulator and water bath
Description: Cold Pressor Test
Study NCT00914173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medoc TSA 2000
Description: Thermal stimuli pain
Study NCT00892242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT00335153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel
Description: Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
Study NCT00335153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy® 1400 ambulatory infusion pump
Study NCT00335153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG tube
Description: percutaneous endoscopic gastrostomy tube
Study NCT00335153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-tube
Description: jejunal tube
Study NCT04638387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PB125
Description: Nrf2 activator containing active ingredients carnosol, withaferin A, and luteolin.
Study NCT04638387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator to P125
Study NCT01495780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Health Monitoring
Description: 1 year of remote health monitoring of symptoms, medication use, breathing tests, physical activity, and healthcare utilization.
Study NCT02849262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan (CLS001) topical gel
Study NCT02849262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle topical gel